Moreover, CHOP with silencing AURKA enhanced these effects of silencing AURKA on these factors above, indicating that CHOP combined with silencing AURKA had better effects on treating DLBCL via suppressing β-Catenin and RAS- ERK1/2 pathway. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.